HAEMONETICS CORP — Director's Dealing 2021

May 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2021-05-18

Reporting Person: Simon, Christopher (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-18	Common Stock	A	26515	—	Acquired	196745	Direct
2021-05-19	Common Stock	S	1024	$55.19	Disposed	195721	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-18	Non-qualified Stock Option (Right to Buy)	$56.57	A	71733	Acquired	2028-05-18	Common Stock (71733)	Direct

Footnotes

F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3: This number includes unvested RSUs previously reported.

F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.